

STALLERGENES REMAINS COMMITTED TO THE RECOGNITION OF INNOVATIVE PHARMACEUTICAL COMPANIES AND HAS JOINED G5 HEALTH

Antony (France), 21 May 2012 – Stallergenes S.A. (Euronext Paris CAC small) today announces that it has joined G5 Health, a professional association that brings together the leading French healthcare and life science companies.

Stallergenes is a French biopharmaceutical company specialised in the treatment of severe allergy related respiratory diseases through allergen immunotherapy. Created 50 years ago by Institut Mérieux, Stallergenes is today the seventh largest pharmaceutical company in France and the leader in its field. More than 500,000 patients are treated with Stallergenes products each year.

Stallergenes thus places innovation at the heart of its strategy by devoting nearly 20% of sales to R&D activities, representing cumulative investment of € 200 million over the last 6 years. Since 2003, this focus on innovation has led to the development of Stalair®, a programme for the development of sublingual tablet's pharmaceutical specialities for the treatment of the principal respiratory allergies worldwide.

Thanks to strong and steady growth, Stallergenes has been contributing to creating value in France and intends to participate in the public debate on the role of innovative pharmaceutical companies in this country. Stallergenes wished to join G5 Health to make an active contribution to the debate about implementing a policy to bolster France's position as a development platform for pharmaceutical companies investing in research.

Roberto Gradnik, Chief Executive Officer of Stallergenes, said: "Our goal is to become a global pharmaceutical company, leveraging a sound base established on our domestic market. Stallergenes is proud of its 50-year long record of creating value in France. Joining G5 Health is for us the opportunity to contribute to the public debate on the essential role played by innovative healthcare companies in our country, and on France's international influence in the pharmaceutical field."

About G5 HEALTH

G5 Health, the voice for the French health industry, is a forum for the leaders of the major health and bio-sciences companies in France (bioMérieux, Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi and Stallergenes). These groups have chosen France as the base for their international development, and they make R&D their priority. The members of the G5 Health share 5 ambitions: to gain recognition for the crucial contribution of the life sciences in public health in France, to help to restore France's competitive position, to commit strongly to increase excellence in French bio-medical research, to improve patients' access to health solutions and to support the biotechnology and new technology sectors.

For further information please visit: <http://www.g5.asso.fr>

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company specialised in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma. The seventh largest pharmaceutical company in France and the leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross turnover to Research & Development and is actively involved in the development of a new therapeutic class, sublingual immunotherapy tablets.

In 2011, the company had sales of €235 million and more than 500,000 patients were treated with Stallergenes products.

Euronext Paris (Compartment B)

CAC small

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP



For further information, please visit our website: <http://www.stallergenes.com>

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Contacts

Roberto Gradnik, Chief Executive Officer
Tel. +33 1 55 59 20 04

Investor and Analyst Relations

Christian Thiry, Chief Financial Officer
Tel: +33 1 55 59 20 95
e-mail: investorrelations@stallergenes.fr

Pavie Finance: Lucile de Fraguier
Tel: +44 208 248 2793
e-mail: contact@pavie-finance.com

Stallergenes Press Relations

Lise Lemonnier, Communication Director
Tel: + 33 1 55 59 20 96
e-mail: llemonnier@stallergenes.fr

Chandler Chicco Agency: Bahar Turkoglu
Tel: + 33 1 41 43 02 27
e-mail: bturkoglu@ccapr.com